Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sb_scFv-A-HL
- Development stage
- Preclinical
- Lead developer
- Washington University in St. Louis
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Oral
01
Overview
Sb_scFv-A-HL is an engineered probiotic therapeutic consisting of the yeast *Saccharomyces cerevisiae var. boulardii* (Sb) genetically modified to secrete a high-affinity single-chain variable fragment (scFv) designated scFv-A-HL. This secreted scFv specifically targets and neutralizes the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Developed by researchers at Washington University in St. Louis, Sb_scFv-A-HL is designed for oral administration to achieve localized delivery of neutralizing antibodies directly within the gastrointestinal tract. This approach aims to prevent viral entry, mitigate acute gastrointestinal symptoms such as diarrhea, and potentially target persistent viral reservoirs implicated in long COVID, while bypassing the degradation and systemic limitations of traditional intravenous biologics.
- Other names
- Saccharomyces boulardii expressing scFv-A-HLSaccharomyces boulardii secreting scFv-A-HLscFv-A-HL-secreting Saccharomyces boulardii
02
Targets
ACE2 (Angiotensin-converting enzyme 2)RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on Sb_scFv-A-HL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sb_scFv-A-HL.